Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00439465 · OUTCOME

Time to Recovery of Platelet Count

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma · Source last updated 2019-03-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
Full Range
Time frame
From initiation of treatment on protocol until Day 100

What was measured

To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.

Groups in this outcome

Ex-vivo Expanded Effector Cells

Infusing IL-2 and GM-CSF post-HCST Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ex-vivo Expanded Effector Cells19

Reported measurements

Source class 1
Values in days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Ex-vivo Expanded Effector Cells16Not reported1026Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        10
        upper Limit
        26
        value
        16
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.
dispersion Type
Full Range
groups
  1. description
    Infusing IL-2 and GM-CSF post-HCST Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
    id
    OG000
    title
    Ex-vivo Expanded Effector Cells
param Type
MEDIAN
reporting Status
POSTED
time Frame
From initiation of treatment on protocol until Day 100
title
Time to Recovery of Platelet Count
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice